Exabis Library
Welcome to the e-CCO Library!
P574: Population pharmacokinetic and exposure-response analyses for efficacy and safety of risankizumab in subjects with active Crohn‘s disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P574: The effects of vagus nerve stimulation in biologic-refractory Crohn’s disease: A prospective clinical trial
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P575 Real-world effectiveness and safety of ustekinumab for the treatment of refractory Crohn’s disease: The Scottish ustekinumab cohort
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P575: AZA-related toxicity isn't aggravated by concomitant drugs in IBD patients
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P575: Effect of etrasimod on immune cell subsets in colonic tissue of patients with ulcerative colitis: immunophenotyping analysis of colon biopsy samples from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P575: Nutrition and Inflammatory Bowel Disease – a nationwide survey of patients, gastroenterologists and dietitians
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P575: Safety and efficacy of autologous haematopoietic stem cell transplantation for refractory Crohn’s disease after cyclophosphamide-free mobilisation: Preliminary Results
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P575: Simple novel tacrolimus enemas are very effective in severe refractory proctitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P575: Vedolizumab trough levels predict clinical outcomes in inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P576 The value of small bowel capsule endoscopy in the change of therapeutic management in patients with established Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P576: Could the hyperbaric oxygen therapy be an effective adjuvant therapy for fistulising Crohn's disease?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P576: Endoscopic healing with vedolizumab in Crohn's disease occurs predominantly in the first 6 months and is independent of serum concentrations: Data from LOVE-CD
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P576: Impact of improved access to biologic therapies and physician engagement on excess steroid exposure: Results from a UK audit of 3561 patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P576: Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn’s disease: a Belgian multi-centric cohort study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P576: Therapeutic drug monitoring as predictive marker of mucosal healing in Crohn’s disease patients treated with anti-TNF: a prospective multi-centre study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P576: Ustekinumab levels correlate with induction fecal calprotectin drop-slope and discriminate the need for intensification at week 52 in Crohn's Disease patients.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P577 Ustekinumab in actual clinical practice: our centre experience
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P577: “Treat to target” recommendations in ulcerative colitis in practice: clinician perceptions and potential barriers
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P577: A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the Nucleotide-binding oligomerization domain, Leucine rich Repeat containing X1 (NLRX1) agonist NX-13 in Ulcerative Colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P577: A propensity score-matched comparison of infliximab and adalimumab in naïve and non-naïve patients with Crohn’s disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM